Compile Data Set for Download or QSAR
Report error Found 246 Enz. Inhib. hit(s) with all data for entry = 3415
LigandPNGBDBM399979(US10323042, Example 58)
Affinity DataIC50: 1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399978(US10323042, Example 57 | US10738063, Example 57)
Affinity DataIC50: 1.86nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399927(US10323042, Example 7 | (6S)-3-(4-Chloro-2,5-diflu...)
Affinity DataIC50: 2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399928(US10323042, Example 8 | 3-(4-Chloro-2-methylphenyl...)
Affinity DataIC50: 5.29nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399973(US10323042, Example 53A | US10323042, Example 53B ...)
Affinity DataIC50: 5.35nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399978(US10323042, Example 57 | US10738063, Example 57)
Affinity DataIC50: 5.66nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399973(US10323042, Example 53A | US10323042, Example 53B ...)
Affinity DataIC50: 6.45nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399927(US10323042, Example 7 | (6S)-3-(4-Chloro-2,5-diflu...)
Affinity DataIC50: 6.51nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399979(US10323042, Example 58)
Affinity DataIC50: 8.52nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399973(US10323042, Example 53A | US10323042, Example 53B ...)
Affinity DataIC50: 10.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399937(US10323042, Example 17 | US10738063, Example 17)
Affinity DataIC50: 11nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399971(US10323042, Example 51 | US10738063, Example 51)
Affinity DataIC50: 12nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399968(US10323042, Example 48 | US10738063, Example 48)
Affinity DataIC50: 12.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399969(US10323042, Example 49 | US10738063, Example 49)
Affinity DataIC50: 13.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399926(US10323042, Example 6 | (6S)-3-(4-Chloro-2-methylp...)
Affinity DataIC50: 14.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399967(US10323042, Example 47 | US10738063, Example 47)
Affinity DataIC50: 15.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399979(US10323042, Example 58)
Affinity DataIC50: 16.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399960(US10323042, Example 40 | US10738063, Example 40)
Affinity DataIC50: 19.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399964(US10323042, Example 44 | US10738063, Example 44)
Affinity DataIC50: 20.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399937(US10323042, Example 17 | US10738063, Example 17)
Affinity DataIC50: 21.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399938(US10323042, Example 18 | US10738063, Example 18)
Affinity DataIC50: 23.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399975(US10323042, Example 54 | US10738063, Example 54)
Affinity DataIC50: 25.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399958(US10323042, Example 38 | US10738063, Example 38)
Affinity DataIC50: 26.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399971(US10323042, Example 51 | US10738063, Example 51)
Affinity DataIC50: 26.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399923(US10323042, Example 3 | Azetidin-1-yl[3-(4-chloro-...)
Affinity DataIC50: 27.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399928(US10323042, Example 8 | 3-(4-Chloro-2-methylphenyl...)
Affinity DataIC50: 28.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399978(US10323042, Example 57 | US10738063, Example 57)
Affinity DataIC50: 28.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399973(US10323042, Example 53A | US10323042, Example 53B ...)
Affinity DataIC50: 29.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399927(US10323042, Example 7 | (6S)-3-(4-Chloro-2,5-diflu...)
Affinity DataIC50: 31.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399923(US10323042, Example 3 | Azetidin-1-yl[3-(4-chloro-...)
Affinity DataIC50: 31.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399939(US10323042, Example 19)
Affinity DataIC50: 32.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399925(US10323042, Example 5 | 3-(4-Cyano-5-fluoro-2-meth...)
Affinity DataIC50: 34.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399936(US10323042, Example 16 | US10738063, Example 16)
Affinity DataIC50: 36.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399934(US10323042, Example 14 | US10738063, Example 14)
Affinity DataIC50: 37.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399963(US10323042, Example 43 | US10738063, Example 43)
Affinity DataIC50: 38nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399970(US10323042, Example 50 | US10738063, Example 50)
Affinity DataIC50: 40.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399938(US10323042, Example 18 | US10738063, Example 18)
Affinity DataIC50: 40.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399959(US10323042, Example 39 | US10738063, Example 39)
Affinity DataIC50: 44nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399926(US10323042, Example 6 | (6S)-3-(4-Chloro-2-methylp...)
Affinity DataIC50: 44.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399967(US10323042, Example 47 | US10738063, Example 47)
Affinity DataIC50: 45.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399936(US10323042, Example 16 | US10738063, Example 16)
Affinity DataIC50: 46nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399952(US10323042, Example 32 | US10738063, Example 32)
Affinity DataIC50: 48.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399933(US10323042, Example 13 | US10738063, Example 13)
Affinity DataIC50: 50.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399960(US10323042, Example 40 | US10738063, Example 40)
Affinity DataIC50: 53.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399964(US10323042, Example 44 | US10738063, Example 44)
Affinity DataIC50: 55.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399956(US10323042, Example 36 | US10738063, Example 36)
Affinity DataIC50: 56nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399933(US10323042, Example 13 | US10738063, Example 13)
Affinity DataIC50: 57nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399935(US10323042, Example 15 | US10738063, Example 15)
Affinity DataIC50: 57.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399968(US10323042, Example 48 | US10738063, Example 48)
Affinity DataIC50: 63.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM399965(US10323042, Example 45 | US10738063, Example 45)
Affinity DataIC50: 64nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 246 total ) | Next | Last >>
Jump to: